Latest Asx News

American Rare Earths reports strong metallurgical leach recoveries and significantly reduced impurities at its Halleck Creek Rare Earths Project, marking a key step toward economic production of critical rare earth elements in the US.

Future Generation Global has reported a strong 20.8% investment portfolio return for the year ending June 2025, prompting an increase in its fully franked interim dividend to 4.0 cents per share. This marks the sixth consecutive year of dividend growth for the ASX-listed investment company.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Lord Resources has successfully raised $1.39 million through a shortfall placement, setting the stage for imminent drilling at its high-grade Ilgarari Copper Project in Western Australia.

Javelin Minerals has announced a significant 27% increase in the Indicated Resource at its Eureka Gold Project in Western Australia, alongside a 16% grade improvement, setting the stage for expanded near-term mining plans.

ClearVue Technologies’ solar façade trial at Hong Kong EMSD headquarters reveals a rapid 2.6-year payback period with government incentives, alongside strong thermal and fire safety performance.

DigitalX Limited reports a $75.6 million treasury valuation driven by Bitcoin and digital assets, completing a $20.7 million capital raise to expand its Bitcoin-first strategy.

Catalina Resources has launched a reverse circulation drilling campaign at its Laverton project, aiming to extend high-grade rare earth and gold mineralisation just 2km from the Mt Weld mine. The program seeks to confirm structural links to one of the world’s richest rare earth deposits.

Scalare Partners Holdings has voluntarily suspended trading on the ASX as it prepares to announce a capital raising tied to its planned acquisition of Tank Stream Labs.

Alliance Nickel has strengthened its financial position with an additional A$1.2 million unsecured loan and extended existing facilities, while reaffirming the commercial viability of its NiWest Nickel-Cobalt Project through a comprehensive Definitive Feasibility Study.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Dalaroo Metals has raised $1 million through a strategic placement supported by cornerstone investors including local partners in Cote d’Ivoire, while announcing the resignation of its CEO. The funds will accelerate exploration across multiple regions and support new project evaluations.